글로벌 동맥경화증 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

플라그가 쌓여서 정맥이 좁아지는 현상을 죽상경화증이라고 합니다. 죽상경화증은 동맥에 영향을 미치는 동맥경화증의 한 유형입니다. 이 질환은 몸 전체로의 혈류를 방해하여 심각한 심혈관 위험을 초래합니다. 내피가 손상되면 LDL 콜레스테롤이 동맥벽에 축적되어 죽상경화증을 일으킵니다. 콜레스테롤을 정화하기 위해 신체는 대식세포의 흰 혈소판을 보냅니다. 그러나 세포가 때때로 영향을 받은 부위에 붙어 있을 수 있습니다. 일정 시간이 지나면 나쁜 콜레스테롤(LDL 콜레스테롤)과 대식세포의 흰 혈소판으로 구성된 플라그가 형성됩니다. 플라그가 통로를 막아 몸 전체로의 혈류가 방해를 받습니다.

Data Bridge Market Research는 2021년에 동맥경화증 시장이 25억 5천만 달러 규모였으며 2029년까지 41억 1천만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 6.16%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

시간이 지남에 따라 동맥을 둘러싼 콜레스테롤 플라크로 인해 동맥이 굳어지고 수축되는 현상을 죽상경화증이라고 합니다. 죽상경화증은 고콜레스테롤 및 고혈압 치료제를 복용하면 진행이 느려지거나 중단됩니다. 이 약물은 심장마비나 뇌졸중의 위험을 줄여줍니다. 의사는 더 침습적인 시술을 통해 죽상경화성 막힘을 뚫을 수 있습니다. 우회 수술은 신체 다른 부위의 혈관이나 합성 튜브를 사용하여 막히거나 좁아진 동맥 주위로 혈액을 돌리는 것을 말합니다. 혈전 용해 요법은 혈전을 용해하기 위해 약물을 동맥에 주입하는 것을 말합니다. 한쪽 끝에 날카로운 칼날이 있는 카테터를 사용하여 동맥에서 플라크를 제거하는 것을 죽상 절제술 이라고 합니다 .

동맥경화 시장 동향

운전자

• 심혈관 질환 의 유병률 증가

전 세계적으로 심혈관 질환 의 유병률이 증가함에 따라 시장 성장이 촉진될 것으로 추정됩니다. European Heart Network에 따르면, 심혈관 질환은 매년 유럽에서 390만 명의 사람들에게 영향을 미치고 있으며, 유럽 연합에서 180만 명 이상이 사망합니다. 부유한 나라에서는 앉아서 생활하는 생활 방식이 심혈관 질환의 가장 높은 비율을 차지합니다. 또한, 조사된 시장은 앉아서 생활하는 생활 방식으로 인해 심혈관 질환의 유병률이 높고 치료 선택에 대한 인식이 높아짐에 따라 주도될 것으로 예상됩니다.

• 의료 인프라에 대한 투자 증가

Another significant factor influencing the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to cardiovascular diseases, further estimated to enhance the risk of atherosclerosis in this age group.

• Rising incidences of high cholesterol and obesity

The rising incidences of obesity and high cholesterol is expected to flourish the market's growth rate by increasing the risk of atherosclerosis. In 2018, the World Health Organization estimates that 40 million children under the age of five were overweight or obese, according to the world health organization (WHO). Increased consumption of high-fat, high-sugar foods and rise in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization are all contributing to high cholesterol rates, resulting in high growth of market.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the atherosclerosis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of atherosclerosis market. Rising level of disposable income and high prevalence of high blood pressure are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the atherosclerosis market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

• Popularity of Generic Drugs

Due to several recalls of valsartan products manufactured by several brands, the US Food and Medication Administration approved a novel generic drug of Diovan in March 2019 to bridge the high demand and poor supply gap of this vital drug. After two months, Zydus Cadila reported that Chlorthalidone, a generic counterpart of Thalitone made by Pfizer, had been approved. This will create new market opportunities in coming years.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for atherosclerosis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the atherosclerosis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This atherosclerosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the atherosclerosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Atherosclerosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Atherosclerosis Market Scope

The atherosclerosis market is segmented on the basis of stages, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Stages

• Endothelial Damage and Immune Response
• Fatty Streak
• Plaque Growth
• Plaque Rupture

Diagnosis

• Ankle-brachial Index (ABI)
• Doppler Ultrasound
• Echocardiogram
• Electrocardiogram (ECG)
• Blood Tests
• Others

Treatment

• Medication
• Anti-Platelet Drugs
• Cholesterol Lowering Medications
• Beta Blockers
• Angiotensin-Converting Enzyme (Ace) Inhibitors
• Calcium Channel Blockers
• Others
• Surgery
• Coronary artery bypass surgery
• Fibrinolytic therapy
• Endarterectomy
• Angioplasty
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Atherosclerosis Market Regional Analysis/Insights

The atherosclerosis market is analysed and market size insights and trends are provided by country, stages, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the atherosclerosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the atherosclerosis market because of the rising prevalence of atherosclerosis and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Atherosclerosis Market Share Analysis

The atherosclerosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to atherosclerosis market.

Some of the major players operating in the atherosclerosis market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 히크마 제약(영국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• Bayer AG(독일)
• 베링거 인겔하임 인터내셔널 GmbH. (독일)
• Dr. Reddy's Laboratories Ltd. (인도)
• 길리드 사이언스 주식회사(미국)
• 암젠 주식회사(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• AbbVie Inc.(미국)
• 루팡(인도)
• 알러간(아일랜드)

SKU-53468